MAPT and tauopathy: In a very recently published paper, our group found that flortaucipir uptake did not correlate with a specific type of tau lesion in 4R tauopathies, demonstrating no differential affinity.79 Alternatively, tracers that preferentially bind to either neuronal or glial tau lesions could potentially differentiate PSP from CBD based on the topography and magnitude of uptake.